Sweet dreams: glycosylation controls tumor cell dormancy.
- Resource Type
- Academic Journal
- Authors
- Bresnahan E; Department of Medicine, Division of Hematology and Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, USA.; Bravo-Cordero JJ; Department of Medicine, Division of Hematology and Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, USA. Electronic address: josejavier.bravo-cordero@mssm.edu.
- Source
- Publisher: Cell Press Country of Publication: United States NLM ID: 101665956 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-8025 (Electronic) Linking ISSN: 24058025 NLM ISO Abbreviation: Trends Cancer Subsets: MEDLINE
- Subject
- Language
- English
In a recent study in Cancer Cell, Sreekumar et al. used therapy-associated breast cancer mouse models as well as in vitro dormancy models to identify extracellular matrix (ECM)-related tumor cell-autonomous mechanisms of dormancy in residual tumor cells (RTCs). The study reveals an important role of the glycosylation of proteoglycans in sustaining dormancy and opens the door to leverage this biology to eliminate RTCs and prevent recurrence.
Competing Interests: Declaration of interests No interests are declared.
(Copyright © 2024 Elsevier Inc. All rights reserved.)